Prevalence of Creutzfeldt-Jakob Disease in Australia
The prevalence of CJD in Australia is approximately 1.0-1.4 cases per million population per year, consistent with global sporadic CJD rates.
Current Epidemiological Data
The most recent Australian surveillance data demonstrates stable incidence rates:
- Annual incidence rate: The overall annual mortality rate for sporadic CJD (sCJD) in Australia reached 1.03 per million for the period 1990-1999, peaking at 1.4 per million in 1999 1
- Recent surveillance: In 2022, the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR) identified 38 confirmed or probable prion disease cases (15 definite, 23 probable) from 79 suspected notifications 2
- International comparison: Australia's rates align with the multinational European-Australian-Canadian study showing an overall annual mortality rate of 1.39 per million for sporadic CJD between 1999-2002 3
Disease Distribution Patterns
Etiologic Subtypes in Australia
The breakdown of CJD cases over the 30-year surveillance period (1970-1999) shows 1:
- Sporadic CJD: 90.7% of all cases (the vast majority)
- Heredofamilial CJD: 7.2% of cases
- Iatrogenic CJD: 2.1% of cases
- Variant CJD: No cases identified in Australia through 2022 2, 4
Temporal Trends
There has been a progressive increase in reported incidence over time, though this reflects improved case ascertainment rather than true disease increase 1:
- 1970-1979: 0.31 per million per year
- 1980-1989: 0.77 per million per year
- 1990-1999: 1.03 per million per year
Population-Specific Considerations
Indigenous Australians
CJD occurs in Indigenous Australians at rates similar to the general population 5:
- Crude annual rate: 0-3.87 per million (not significantly different from non-Indigenous Australians at 0.94-1.83 per million)
- Standardized mortality ratio: 1.49 (95% CI, 0.75-2.98), indicating no significant difference from the all-resident Australian population
- Clinical phenotype: Similar presentation to non-Indigenous cases, with median age at death of 61 years and median disease duration of 3 months 5
Surveillance Infrastructure
The ANCJDR maintains comprehensive national surveillance 2:
- Diagnostic testing volume: 599 cerebrospinal fluid specimens referred for 14-3-3 protein testing in 2022
- Autopsy confirmation rate: 55% of suspected prion disease deaths underwent neuropathological examination in 2022 2
- Surveillance period: Prospective nationwide surveillance since October 1993, with retrospective data from 1970 2
Global Context
Australia's CJD prevalence aligns with the established global pattern for sporadic CJD of approximately 1.5-2.0 cases per million person-years 6. The multinational study including Australia demonstrated mortality rates were similar across all participating countries, with no evidence of geographic clustering or novel disease variants outside of variant CJD in the United Kingdom 3.
Clinical Implications
The stable prevalence rate in Australia means clinicians should maintain appropriate clinical suspicion for CJD in patients presenting with rapidly progressive dementia, particularly given that death certificates have only 83.0% sensitivity for detecting sporadic CJD cases 1. The ANCJDR provides diagnostic support through CSF 14-3-3 testing and maintains the national surveillance registry for epidemiological monitoring 2.